Effect of a leucine-rich supplement in combination with nutrition and physical exercise in advanced cancer patients: A randomized controlled intervention trial.


Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
12 2020
Historique:
received: 19 11 2019
revised: 28 03 2020
accepted: 04 04 2020
pubmed: 29 4 2020
medline: 20 8 2021
entrez: 29 4 2020
Statut: ppublish

Résumé

Branched-chain amino acids and specifically leucine stimulate protein synthesis and may overcome an anabolic resistance in malnourished and cachectic cancer patients. Therefore, we hypothesized that the addition of a leucine-rich supplement to a multimodal therapy improves physical function in advanced cancer patients. This single center, randomized trial examined a multimodal therapy over 12 weeks in patients with advanced cancer. The intervention group received a leucine-rich supplement in combination with a nutrition and physical exercise program. Patients in the control group received standard care. Primary endpoint was physical function measured with the short physical performance battery (SPPB). Secondary endpoints were further physical performance tests, nutritional status, dietary intake, fatigue, quality of life (QoL) and clinical course. All parameters were evaluated at baseline, after three and at six months. 23 women and 29 men with an average age of 63.1 ± 10.3 (range 30-81) years and BMI of 25.4 ± 4.7 kg/m The present trial demonstrated a good adherence to the multimodal therapy as well as a significant improvement of handgrip strength in patients with advanced cancer. In addition, the clinical course data underlined the safety of the program. However, we failed to show significant improvements in further physical performance tests, especially our primary outcome factor SPPB as well as nutritional status, fatigue or QoL.

Sections du résumé

BACKGROUND & AIMS
Branched-chain amino acids and specifically leucine stimulate protein synthesis and may overcome an anabolic resistance in malnourished and cachectic cancer patients. Therefore, we hypothesized that the addition of a leucine-rich supplement to a multimodal therapy improves physical function in advanced cancer patients.
METHODS
This single center, randomized trial examined a multimodal therapy over 12 weeks in patients with advanced cancer. The intervention group received a leucine-rich supplement in combination with a nutrition and physical exercise program. Patients in the control group received standard care. Primary endpoint was physical function measured with the short physical performance battery (SPPB). Secondary endpoints were further physical performance tests, nutritional status, dietary intake, fatigue, quality of life (QoL) and clinical course. All parameters were evaluated at baseline, after three and at six months.
RESULTS
23 women and 29 men with an average age of 63.1 ± 10.3 (range 30-81) years and BMI of 25.4 ± 4.7 kg/m
CONCLUSIONS
The present trial demonstrated a good adherence to the multimodal therapy as well as a significant improvement of handgrip strength in patients with advanced cancer. In addition, the clinical course data underlined the safety of the program. However, we failed to show significant improvements in further physical performance tests, especially our primary outcome factor SPPB as well as nutritional status, fatigue or QoL.

Identifiants

pubmed: 32340904
pii: S0261-5614(20)30163-1
doi: 10.1016/j.clnu.2020.04.008
pii:
doi:

Substances chimiques

Leucine GMW67QNF9C

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3637-3644

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest There are no conflicts of interest to declare.

Auteurs

Lena J Storck (LJ)

Kantonsspital Winterthur, Department of Medicine, CH-8401, Winterthur, Switzerland.

Maya Ruehlin (M)

Kantonsspital Winterthur, Department of Medicine, CH-8401, Winterthur, Switzerland.

Sabine Gaeumann (S)

Kantonsspital Winterthur, Department of Medicine, CH-8401, Winterthur, Switzerland.

David Gisi (D)

Kantonsspital Winterthur, Institute of Therapy and Rehabilitation, CH-8401, Winterthur, Switzerland.

Martina Schmocker (M)

Kantonsspital Winterthur, Institute of Therapy and Rehabilitation, CH-8401, Winterthur, Switzerland.

Peter J Meffert (PJ)

Corvus, D-17179, Altkalen, Germany.

Reinhard Imoberdorf (R)

Kantonsspital Winterthur, Department of Medicine, CH-8401, Winterthur, Switzerland.

Miklos Pless (M)

Kantonsspital Winterthur, Department of Medicine, CH-8401, Winterthur, Switzerland.

Peter E Ballmer (PE)

Kantonsspital Winterthur, Department of Medicine, CH-8401, Winterthur, Switzerland. Electronic address: peter.ballmer@hispeed.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH